Cell-Free DNA Methylation & Hydroxymethylation Sequencing Solutions
cfDNA methylation data is only as interpretable as the detection route chosen to generate it. Circulating free DNA from plasma or serum is scarce (15–40 ng), heavily fragmented (50–300 bp), and diluted by non-tumour-derived fragments—conditions under which the wrong chemistry can degrade already-limited signal, conflate 5mC with 5hmC, or interrogate too few CpG sites to answer the research question. CD Genomics helps you match the detection route to your evidence need—genome-wide discovery, targeted high-depth validation, hydroxymethylation-specific profiling, or complementary chromatin-level analysis—so that scarce liquid-biopsy material becomes reproducible, decision-grade methylation data for research into early-detection biomarkers, prognosis-associated signatures, and drug-response associations.
Key Highlights of Our cfDNA Methylation Solutions:
- Low-Input Feasibility: Reliable methylation and hydroxymethylation profiles from 15–40 ng of cfDNA, isolated from 1–4 mL of plasma or serum.
- Route-to-Question Matching: Detection chemistry is selected by your evidence need—discovery scanning, targeted validation, hydroxymethylation profiling, or chromatin-level integration—not by a one-size-fits-all default.
- ctDNA-Focused Enrichment: Our exclusive cfDNA extraction kit enriches tumor-derived fragments to maximize the usable signal from low tumour fraction samples.
- End-to-End Delivery: Streamlined from cfDNA isolation and library construction to rigorous QC, sequencing, and publication-ready bioinformatics reporting.
What Is cfDNA Methylation and Why Measure It?
Methylation is the most frequently altered and most stably recoverable epigenetic mark in circulating free DNA (cfDNA)—but its value in liquid-biopsy research depends on whether the detection route can distinguish true tumour-derived signals from dilution noise, chemical degradation artefacts, and conflation between 5mC and 5hmC. cfDNA fragments released into the bloodstream (50–300 bp) carry tissue- and tumour-associated methylation patterns that can support research into early-detection biomarkers, prognosis-associated signatures, and resistance-related changes from a simple blood draw. Yet cfDNA is present at low concentration and is heavily dominated by non-tumour-derived fragments, which places demanding requirements on assay sensitivity, input tolerance, and data interpretation.
Our solutions are engineered around exactly these constraints: matching detection chemistry to sample reality, evidence need, and study stage—rather than forcing every project into a single default assay.
Why cfDNA Methylation Projects Fail Before Sequencing Starts
Most cfDNA methylation projects do not fail at the sequencing step. They fail at the route-selection step—when the detection chemistry is mismatched to the sample reality, the evidence need, or the study stage. Four specific gaps account for the majority of unusable data.
Tumour-derived cfDNA can represent less than 1% of total cfDNA in early-stage cancer. Without selective enrichment of short tumour-derived fragments, tumour-specific methylation marks are masked by background non-tumour DNA—yielding negative results that reflect dilution, not biology.
cfDNA is already 50–300 bp; sodium bisulfite conversion further fragments DNA under harsh acidic conditions. For scarce, degraded samples this can reduce library yield below the threshold needed for reliable methylation calling—the assay fails before a single CpG is measured.
Traditional bisulfite sequencing cannot distinguish 5-methylcytosine (5mC, the stable regulatory mark) from 5-hydroxymethylcytosine (5hmC, an active-demethylation intermediate). Reporting "methylation" that silently includes 5hmC can misassign active-regulation signals as stable epigenetic marks—undermining biomarker specificity.
Whole-genome WGBS (90 Gb) is cost-prohibitive for validating known markers across large cohorts, while a narrow targeted panel interrogates too few sites for unbiased discovery. Choosing the wrong route either wastes budget or loses the answer the study was designed to produce—and the mistake is often discovered only after sequencing is complete.
Technology Decision Guide: Which cfDNA Methylation Route Fits Your Study?
The choice of detection route is the single most consequential decision in a cfDNA methylation project. It determines how many CpG sites you interrogate, at what depth, and which biological question you can answer. Below is a direct comparison of the core sequencing routes we offer for liquid-biopsy methylation and hydroxymethylation analysis; additional compatible technologies are covered in the extended portfolio below.
| Technology | Primary Target | cfDNA Input | Recommended Data | Resolution / Coverage | Best-Fit Research Question |
|---|---|---|---|---|---|
| cfDNA WGBS | Genome-wide 5mC methylation | 15–40 ng | 90 Gb raw (PE150) | Single-base; ~28 million CpG sites | Unbiased discovery of novel methylation biomarkers across the whole genome |
| EM-seq | Genome-wide combined 5mC + 5hmC signal | 15–40 ng | 90 Gb raw (PE150) | Single-base; ~28 million CpG sites | Whole-genome profiling with gentler enzymatic conversion for limited or degraded cfDNA; standard EM-seq does not distinguish 5mC from 5hmC |
| cfDNA Reduced-Representation Route | Reduced-representation 5mC | Approximately 1–20 ng; feasibility review required | 20 Gb planning reference; CpG depth is project dependent | Single-base; CpG-dense regions (~3–5 million CpG sites) | Low-input profiling of promoter and CpG-island methylation when the reduced-representation workflow is compatible with the available cfDNA |
| cfMeDIP-seq | 5mC enrichment | 5–20 ng | 10 Gb raw | Enrichment-based; 300–600 bp fragment resolution | Ultra-low-input methylome screening and cell-of-origin model research with limited cfDNA consumption |
| Human Methylome Panel 3.4M / 2.0M | Targeted CpG capture | 15–40 ng | 15 Gb (3.4M) / 10 Gb (2.0M) | Single-base; high depth at 3.4M or 2.0M CpG sites | High-depth interrogation of known marker regions; large-cohort validation; low-frequency signal detection |
| Target-BS / Targeted DNA Methylation | Gene-panel bisulfite sequencing | 10–40 ng | 1–10 Gb (panel size dependent) | Single-base; hundreds to thousands of loci | Focused validation of candidate biomarkers across large cohorts at minimal cost per sample |
| 5hmC-Seal | Genome-wide 5hmC enrichment | 15–40 ng | 20M reads (IP + Input) | Enrichment-based; genome-wide 5hmC landscape | Profiling active gene-regulation marks in stem cells, development, and tumour biology |
| ACE-seq | Genome-wide 5hmC, base-resolution | 15–40 ng | 90 Gb raw (PE150) | Single-base; ~28 million CpG sites | Base-resolution 5hmC mapping with minimal DNA damage—an alternative to 5hmC-Seal when single-base resolution is required |
| 5-Base Sequencing | 5mC + genetic variants (SNV / Indel / CNV) | 1–20 ng; 10–20 ng recommended | 90 Gb raw (PE150) | Single-base methylation + variant calling on the same reads | One-library co-detection of methylation and driver mutation from scarce cfDNA—eliminates split-sample bias when both layers are needed |
| TAPS+ | Combined 5mC + 5hmC signal and genetic variants (SNV / SV / Indel) | 15–40 ng | 90 Gb raw (PE150) | Single-base; non-destructive 5mC/5hmC→T conversion, genome intact | Non-destructive conversion that helps preserve cfDNA fragments; one library provides methylation, variant, and structural evidence while reducing cross-library variability |
Selection Strategy
- Unbiased genome-wide discovery: Choose cfDNA WGBS for a comprehensive methylation map without predefined targets. If the cfDNA is highly degraded or gentler conversion is preferred, EM-seq provides an enzymatic alternative.
- Very limited cfDNA input: Consider reduced-representation or enrichment-based routes. The final route should be confirmed against sample quality, library complexity, and the genomic breadth required by the study.
- Known markers or cohort validation: Use the Human Methylome Panel (3.4M/2.0M), Target-BS, or another targeted DNA methylation route when defined regions require deeper, cost-efficient coverage.
- 5hmC-focused research: Choose 5hmC-Seal for sensitive enrichment-based profiling or ACE-seq for base-resolution mapping. Use a dedicated 5hmC route whenever 5hmC must be interpreted separately.
- Methylation plus genetic evidence: Choose 5-Base Sequencing or TAPS+ when the same cfDNA must support methylation analysis together with variant or structural evidence.
- Specialized project extensions: Consider cfDNA-targeted capture, oxBS-seq, hMeDIP-seq, or cfChIP-seq when the study requires focused capture, an alternative hydroxymethylation strategy, or cell-free chromatin evidence. These options are detailed in the extended technology portfolio below.
Extended Technology Portfolio for cfDNA Projects
Beyond the core sequencing routes above, our platform supports complementary technologies across a cfDNA research program—from matched tissue or genomic-DNA array screening and cfDNA-targeted capture to alternative hydroxymethylation assays, chromatin profiling, and multi-omics integration. Selecting the right combination lets you match assay resolution, input requirement, and cost to each stage of your study.
When sufficient tissue-derived or genomic DNA is available, Illumina methylation arrays can provide a standardized route for reference-cohort screening and candidate-region nomination. Options include Human DNA Methylation Assay (850K), 935K, and 270K. These BeadChip workflows should not be treated as equivalent to low-input cfDNA capture sequencing.
Depending on whether you need base resolution or enrichment depth, additional 5hmC routes are available: oxBS-seq for precise 5mC/5hmC discrimination, hMeDIP-seq for antibody-based 5hmC enrichment, and the DNA Hydroxymethylation Analysis service for targeted hydroxymethylation profiling.
Methylation is not the only regulatory layer recoverable from liquid biopsy. cfChIP-seq profiles histone modifications on nucleosome-bound cfDNA fragments, revealing transcription-factor and enhancer activity states—an orthogonal layer that can be integrated with cfDNA methylation for a more complete picture of tumour regulatory biology.
To validate candidate methylation markers identified in discovery phases, our bisulfite sequencing PCR and CpG Island Panel services deliver focused, high-depth confirmation at single-base resolution. For broader cfDNA confirmation, cfDNA 935K-Capture BS is a supplier-described liquid-hybridization capture sequencing route designed around Infinium MethylationEPIC v2.0 loci and their flanking sequences; it is distinct from direct BeadChip hybridization. Supplier specifications report more than four times as many interrogated CpG sites as the 935K array, overall target coverage above 98%, coverage at 20× above 90%, and 20%-of-mean-depth uniformity above 95%. Actual performance depends on cfDNA quality, library complexity, capture design, and sequencing depth and should be confirmed for the individual project.
Every cfDNA methylation route is backed by a complete analysis pipeline, and for studies combining methylation with other layers we provide custom epigenomic data analysis and integrating RNA-seq and epigenomic data analysis—connecting cfDNA methylation signals to transcriptomic and chromatin evidence for mechanism-level conclusions.
Core Technical Advantages
Our liquid-biopsy workflows are optimized around the three failure points that most often derail cfDNA methylation projects: limited input material, low tumour-derived signal, and data that cannot be interpreted. Each protocol step is designed to protect the scarce, fragmented signal in your sample.
- Low Starting Volume, Preserved Signal: Robust libraries are generated from as little as 15–40 ng of cfDNA purified from 1–4 mL of plasma or serum. Gentle extraction and conversion steps minimize the additional fragmentation that bisulfite-based chemistry can cause, so a higher proportion of the original cfDNA molecules survives to sequencing.
- Exclusive ctDNA Enrichment Kit: Our in-house cfDNA extraction kit is formulated to selectively enrich tumour-derived short fragments, raising the effective tumour fraction available for methylation calling—critical for early-stage samples where ctDNA is present at very low abundance.
- Route Flexibility Matched to Budget: From whole-genome discovery to ultra-low-input options, targeted deep capture, reference-array screening, and single-library multi-base assays—you pay only for the data your research question requires, with sequencing strategies pre-optimized for each route.
- Reproducible, Interpretable Output: Every project receives methylation calls per CpG site, differential methylation statistics with nearest-gene annotation, CpG-rich region maps, and coverage/methylation-level histograms—structured so the biology, not the bioinformatics, leads your manuscript.
Exact analyses, deliverables, and output formats are finalized according to the selected technology, sample quality, study design, and agreed project scope.
Applications in Liquid Biopsy Research
cfDNA methylation profiling bridges basic epigenomics and translational oncology. Its non-invasive nature makes it uniquely suited to longitudinal sampling and early-disease studies where tissue biopsy is impractical or repeatedly required.
Identify cfDNA methylation markers associated with early-stage cancer or precancerous conditions and evaluate their potential in research assay development. Genome-wide routes can support candidate discovery, followed by targeted panel testing in independent research cohorts.
Study tumour-associated methylation signals longitudinally and evaluate their relationships with prognosis, post-treatment change, or recurrence-related research endpoints. Deep targeted capture can support investigation of low-abundance residual signals in appropriately designed cohorts.
Profile methylation changes associated with treatment response and acquired resistance. Correlating cfDNA methylation dynamics with defined research outcomes can support prioritization of candidate response- or resistance-associated biomarkers for subsequent validation.
Investigate whether tissue-associated methylation patterns can support statistical tissue-of-origin inference in research cohorts. Combining methylation profiling with custom epigenomic data analysis can support development and evaluation of multi-cancer research models.
Comprehensive cfDNA Methylation Bioinformatics Pipeline
Liquid-biopsy data demands bioinformatics that can distinguish true low-frequency methylation changes from noise introduced by amplification bias and technical variability. We provide an end-to-end analysis pipeline that converts raw FASTQ reads into statistically supported, publication-ready results. For bespoke downstream integration, our team also offers custom epigenomic data analysis.
Standard Methylation Profiling:
- Raw Data QC & Alignment: Adapter trimming and quality filtering remove low-quality reads, followed by alignment of the short cfDNA fragments to the reference genome with bisulfite-aware aligners. Deduplication and methylation-calling pipelines (e.g., Bismark) convert aligned reads into per-CpG methylation calls with strand-specific accuracy.
- Methylation Call & Percentage: Each interrogated CpG site is reported with its methylation call and the percentage of methylated reads, providing the granular quantitative data needed for downstream comparisons.
- Differential Methylation Statistics: Statistically significant differentially methylated loci between experimental groups are identified with appropriate multiple-testing correction, and each locus is annotated with its nearest gene and its relative position (promoter, gene body, intergenic).
- CpG-Rich Region Mapping: Differentially methylated regions (DMRs) are mapped across chromosomes, giving an overview of the genomic distribution of methylation changes and prioritizing candidate regions for functional validation.
Advanced & Integrative Analysis:
- Coverage & Methylation-Level Histograms: Distribution plots of CpG coverage and methylation levels confirm assay robustness and allow rapid visual assessment of data quality across samples.
- Tumour Fraction & Signal-Origin Assessment: For cancer applications, we can estimate tumour-derived signal contribution and, when requested, evaluate tissue-of-origin signals using methylation deconvolution approaches.
- Pathway & Functional Annotation: Significant DMRs are mapped to genes and pathways to connect methylation changes to the biological processes most relevant to your disease model.
- Multi-Omics Integration: When matched RNA-seq or other epigenomic datasets exist, we can integrate methylation with transcriptional or chromatin data to strengthen mechanistic conclusions.
Publication-Ready Demo Results
Our deliverables are structured so that the standard report can move directly into your manuscript's results and supplementary sections. Representative outputs include the following.
- Methylation Call Report: Per-site methylation calls with percentage methylation, enabling quantitative comparison between case and control groups at single-CpG resolution.
- Differential Methylation Volcano Plot: Highlights statistically significant, differentially methylated loci between experimental and control groups, prioritizing candidates for functional validation.
- DMR Chromosome Map: A genome-wide overview of differentially methylated region distribution, allowing rapid identification of methylation hotspots and their chromosomal context.
- CpG Coverage Histogram: Confirms sequencing depth uniformity across the interrogated CpG space, supporting the reliability of downstream calls.
- Methylation-Level Distribution: Histograms of methylation levels per sample reveal global methylation behaviour and flag any batch effects or technical outliers.
These outputs are representative. The final analysis modules, figures, report components, and file formats depend on the selected route and are confirmed during project scoping.
End-to-End Workflow & Strict QC Checkpoints
Every project follows a disciplined pipeline with QC gates at each stage, ensuring that degraded liquid-biopsy material is handled consistently and reproducibly from receipt to final report.
- Sample QC & cfDNA Extraction: Plasma or serum samples (1–4 mL) are assessed for quality, and cfDNA is isolated with our exclusive extraction kit designed to enrich short tumour-derived fragments. cfDNA concentration and fragment distribution are verified by fluorometry and capillary electrophoresis.
- Library Preparation: Depending on the chosen route, cfDNA undergoes bisulfite conversion (WGBS, RRBS, Target-BS), enzymatic conversion (EM-seq, TAPS+), enrichment (MeDIP-seq, 5hmC-Seal, hMeDIP-seq), targeted CpG capture (Human Methylome Panel, Targeted DNA Methylation), or enzymatic modified-base conversion (5-Base), followed by adapter ligation and index-tagged library construction. Array workflows are reserved for compatible tissue-derived or genomic DNA and proceed to Illumina BeadChip hybridization instead.
- Library QC & Sequencing: Library concentration and fragment size are validated before paired-end sequencing (PE150) on Illumina platforms at the pre-defined data volume for your route (90 Gb WGBS/EM-seq, 15/10 Gb Panel, or 20M reads 5hmC-Seal).
- Bioinformatics Analysis: Raw reads are processed through the full methylation pipeline—QC, alignment, deduplication, methylation calling, differential analysis, and functional annotation—as described in the bioinformatics section.
- Data Delivery & Reporting: A comprehensive report is compiled with per-site methylation calls, differential statistics, DMR maps, and distribution histograms, alongside raw FASTQ files, aligned reads, and read counts in raw and normalized formats.
Sequencing strategy, data-delivery components, and output formats are route- and project-dependent and are finalized after sample and analysis review.
Sample Requirements
Proper collection and storage of liquid-biopsy samples are the most critical factors in obtaining high-quality cfDNA methylation data. Please follow the guidelines below to maximize the success of your project.
| Sample Type | Recommended Volume | cfDNA Input | Quality & Condition Requirements | Notes |
|---|---|---|---|---|
| Plasma | 1–4 mL | Typically 15–40 ng; route dependent | For EDTA tubes, separate plasma promptly, typically within 2–4 hours; for stabilization tubes, follow the manufacturer's validated processing window; no visible haemolysis | Preferred sample type; consistent collection and processing help limit white-blood-cell DNA contamination. |
| Serum | 1–4 mL | Typically 15–40 ng; route dependent | Collected in serum-separator tubes; avoid prolonged clotting time; no visible haemolysis | Acceptable, though plasma is generally preferred for lower background cfDNA levels. |
| Purified cfDNA | — | 15–40 ng standard reference; selected workflows may be assessed below this range | Quantified by a sensitive fluorometric method; cfDNA fragment-size profile provided; minimal high-molecular-weight DNA contamination | Please confirm the extraction method, concentration, available volume, and fragment-size data where possible. |
| Selected Low-Input Workflows | — | Approximately 1–20 ng purified cfDNA, depending on route | Pre-project feasibility review and route-specific library QC required | Lower input can reduce library complexity, genomic breadth, or validation depth; acceptance is not guaranteed by concentration alone. |
The amounts above are planning references rather than universal acceptance criteria. Exact sample requirements depend on the selected method, species, collection and extraction history, sample quality, cohort design, and analysis goal. Please discuss your materials with our team before shipment. We can also help with study design, collection strategy, route selection, and customized analysis at any stage of your project.
Discuss Sample RequirementsCase Study: Multimodal cfDNA Whole-Methylome Profiling for Cancer Signal and Tissue-of-Origin Research
Frequently Asked Questions (FAQ)
References
- Yan, Y., et al. "Cell-free DNA: Hope and potential application in cancer." Frontiers in Cell and Developmental Biology, vol. 9, 2021, p. 639233.
- Dasari, A., et al. "ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal–Anal Task Forces whitepaper." Nature Reviews Clinical Oncology, vol. 17, no. 12, 2020, pp. 757–770.
- Bie, F., Wang, Z., Li, Y., et al. "Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization." Nature Communications, vol. 14, 2023, article 6042.
- Liu, J., et al. "Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer." Molecular Cancer, vol. 20, no. 1, 2021, p. 36.
- Shen, S. Y., Burgener, J. M., Bratman, S. V., et al. "Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA." Nature Protocols, vol. 14, 2019, pp. 2749–2780.
- Schutsky, E. K., et al. "Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase." Nature Biotechnology, vol. 36, no. 11, 2018, pp. 1083–1090.
- Liu, Y., et al. "Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution." Nature Biotechnology, vol. 37, 2019, pp. 424–429.
- Füllgrabe, J., Gosal, W. S., Creed, P., et al. "Simultaneous sequencing of genetic and epigenetic bases in DNA." Nature Biotechnology, vol. 41, 2023, pp. 1457–1464.
- Siejka-Zielińska, P., et al. "Cell-free DNA TAPS provides multimodal information for early cancer detection." Science Advances, vol. 7, no. 36, 2021, eabh0534.
All products and services are for Research Use Only and are not intended for diagnostic or therapeutic use.